RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
Authors
Keywords
-
Journal
Trials
Volume 19, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-09
DOI
10.1186/s13063-018-2996-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
- (2017) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
- (2016) Bruce D. Cheson et al. BLOOD
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Invariant NKT Cells Promote CD8+ Cytotoxic T Cell Responses by Inducing CD70 Expression on Dendritic Cells
- (2014) V. Y. Taraban et al. JOURNAL OF IMMUNOLOGY
- Differential Impact of CD27 and 4-1BB Costimulation on Effector and Memory CD8 T Cell Generation following Peptide Immunization
- (2014) J. E. Willoughby et al. JOURNAL OF IMMUNOLOGY
- OX40- and CD27-Mediated Costimulation Synergizes with Anti–PD-L1 Blockade by Forcing Exhausted CD8+T Cells To Exit Quiescence
- (2014) Sarah L. Buchan et al. JOURNAL OF IMMUNOLOGY
- Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma
- (2013) Adam J. Olszewski et al. ANNALS OF HEMATOLOGY
- CD27 costimulation contributes substantially to the expansion of functional memory CD8+T cells after peptide immunization
- (2013) Vadim Y. Taraban et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27-Transgenic Mice
- (2013) L.-Z. He et al. JOURNAL OF IMMUNOLOGY
- Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
- (2012) L. A. Vitale et al. CLINICAL CANCER RESEARCH
- CD70–CD27 Interaction Augments CD8+ T-Cell Activation by Human Epidermal Langerhans Cells
- (2012) Marta E. Polak et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD20 monoclonal antibodies: historical and future perspectives
- (2009) S. H. Lim et al. HAEMATOLOGICA
- Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention
- (2009) Claudia Stolz et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now